Classical chemotherapeutic anti-cancer treatments induce cell death through DNA damage
by taking advantage of the proliferative behaviour of cancer cells. The more recent approach …

Angiogenesis inhibitors targeting the vascular endothelial growth factor (VEGF) signalling
pathways are affording demonstrable therapeutic efficacy in mouse models of cancer and in …

Despite the high doses of radiation delivered in the treatment of patients with glioblastoma
multiforme (GBM), the tumors invariably recur within the irradiation field, resulting in a low …

Despite aggressive surgery, radiotherapy and chemotherapy, malignant gliomas remain
uniformly fatal. To progress, these tumours stimulate the formation of new blood vessels …

The blood-tumor barrier (BTB) is a major obstacle for drug delivery to malignant brain tumors
such as glioblastoma (GBM). Disrupting the BTB is therefore highly desirable but …

Antiangiogenic therapy leads to devascularization that limits tumor growth. However, the
benefits of angiogenesis inhibitors are typically transient and resistance often develops. In …

Using MRI techniques, we show here that normalization of tumor vessels in recurrent
glioblastoma patients by daily administration of AZD2171—an oral tyrosine kinase inhibitor …

Development of hypoxic regions is an indicator of poor prognosis in many tumors. Here, we
demonstrate that HIF1α, the direct effector of hypoxia, partly through increases in SDF1α …

Glioblastomas (GBMs), the most common primary brain tumor in adults, are characterized by
resistance to chemotherapy and radiotherapy. One of the defining characteristics of GBM is …

Pro-angiogenic bone marrow (BM) cells include subsets of hematopoietic cells that provide
vascular support and endothelial progenitor cells (EPCs), which under certain permissive …